AMBBY:OTC-Ambu A/S (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC

Last Closing Price

USD 36.80

Change

0.00 (0.00)%

Market Cap

USD 9.41B

Volume

700.00

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Ambu A/S develops, manufactures, and sells medical devices to hospitals, clinics, and rescue services worldwide. It provides healthcare solutions in the fields of visualization, anesthesia, and patient monitoring and diagnostics. The company offers endoscopy products, such as bronchoscopes and monitors, as well as related airway management products comprising video laryngoscopes, double and single lumen tubes, and endobronchial blockers; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of ECG electrodes; and airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers resuscitators, extrication collars, head immobilizers, CPR breathing barriers, suction pumps, video laryngoscopes, and training manikins. It serves hospitals, rescue services, clinics, etc. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-04 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ESLOY EssilorLuxottica Société ano..

-0.66 (-0.67%)

USD87.41B 54.73 33.57
ESLOF EssilorLuxottica Société ano..

N/A

USD87.16B 54.16 33.57
HOCPF HOYA Corporation

N/A

USD55.46B 44.04 0.25
HOCPY HOYA Corporation

N/A

USD55.37B 43.97 0.25
SDMHF Sartorius Stedim Biotech S.A

N/A

USD53.11B 94.25 64.46
CLPBF Coloplast A/S

N/A

USD42.40B 58.06 6.10
CLPBY Coloplast A/S

N/A

USD39.86B 58.08 6.22
RSMDF ResMed Inc

N/A

USD39.55B 33.65 37.36
SAUHY Straumann Holding AG

+0.09 (+0.09%)

USD30.35B 301.64 129.26
TRUMF Terumo Corporation

-0.48 (-1.20%)

USD30.16B 42.86 0.19

ETFs Containing AMBBY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.82% 22% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.82% 22% F 21% F
Trailing 12 Months  
Capital Gain 3.52% 27% F 31% F
Dividend Return 0.13% 4% F N/A N/A
Total Return 3.65% 25% F 29% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 30.84% 51% F 65% D
Dividend Return 0.16% 10% F 9% F
Total Return 31.00% 51% F 64% D
Risk Return Profile  
Volatility (Standard Deviation) 58.05% 44% F 45% F
Risk Adjusted Return 53.40% 52% F 79% C+
Market Capitalization 9.41B 69% D+ 88% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 205.03 17% F 4% F
Price/Book Ratio 15.68 19% F 11% F
Price / Cash Flow Ratio 31.89 22% F 7% F
EV/EBITDA 16.14 36% F 24% F
Management Effectiveness  
Return on Equity 9.12% 40% F 66% D
Return on Invested Capital 10.11% 62% D- 73% C
Return on Assets 5.26% 61% D- 84% B
Debt to Equity Ratio 52.66% 18% F 34% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.25 69% D+ 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.